British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported fourth-quarter core earnings of 68 cents (25.5 pence), outperforming the consensus forecast of 64 cents. Earnings jumped 10% or 14% at constant currency (cc).
GSK stock is trading higher than the 52-week range of $32.38-$53.38.
GSK’s fourth-quarter sales reached $11.46 billion (8.62 billion British pounds). That’s an 8% increase cc, exceeding analyst estimates of $11.19 billion.
Vaccine sales edged 4% higher (+4% cc) to 2.29 billion pounds. The increase was driven by strong ex-U.S. demand for Shingrix, Arexvy, and Meningitis vaccines, partly offset by lower U.S. demand for Shingrix, Arexvy, and Influenza vaccines, as well as lower International sales of Established vaccines.
Growth in the quarter also benefited from higher Shingrix sales in China.
Shingrix vaccine sales were up 20% to 1.01 billion pounds.
Arexvy sales reached …